A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This multi-center, randomized and exploratory clinical trial is designed to evaluate the
effect of bone metabolism and blood sugar of evogliptin and dapagliflozin in the menopause
female patients with osteopenia and type 2 diabetes.
The trial will evaluate bone metabolism (bone markers and bone density) and blood sugar (AGE
and glucose variability) after 12 weeks and 48 weeks.
This clinical trial conducts in two arms, and each arm recruits 60 subjects.